Guangdong Zhongsheng Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Guangdong Zhongsheng Pharmaceutical CEO'su Yong Hong Chen, Jan2011 tarihinde atandı, in görev süresi 13.83 yıldır. şirketin hisselerinin 1.62% doğrudan sahiptir ve bu hisselerin değeri CN¥ 178.68M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.9 yıl ve 4.9 yıldır.

Anahtar bilgiler

Yong Hong Chen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	13.8yrs
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	5.9yrs
Yönetim Kurulu ortalama görev süresi	4.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yong Hong Chen (53 yo)

13.8yrs

Görev süresi

CN¥498,700

Tazminat

Mr. Yong Hong Chen serves as General Manager of Guangdong Huanan Pharmaceutical Group Co., Ltd. and Guangdong Zhongsheng Pharmaceutical Trade Co., Ltd. Mr. Chen serves as Executive Director of Guangdong Zh...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yong Hong Chen	Chairman & President	13.8yrs	CN¥498.70k	1.62% CN¥ 178.7m
Yuchong Zhang	Vice Chairman & Senior VP	7.9yrs	CN¥311.50k	10.95% CN¥ 1.2b
Chun Hua Long	VP, CFO	14.8yrs	CN¥372.90k	0.43% CN¥ 47.0m
Xi Ping Zhao	VP & Director	1.9yrs	CN¥372.90k	0.92% CN¥ 101.3m
Shuang Liu	Vice President	5.9yrs	CN¥547.40k	Veri yok
Wei Yang	Board Secretary	1.5yrs	Veri yok	Veri yok
Rikang Luo	Vice President	less than a year	Veri yok	0.0012% CN¥ 130.2k

5.9yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 002317 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yong Hong Chen	Chairman & President	13.8yrs	CN¥498.70k	1.62% CN¥ 178.7m
Yuchong Zhang	Vice Chairman & Senior VP	7.9yrs	CN¥311.50k	10.95% CN¥ 1.2b
Chun Hua Long	VP, CFO	10.8yrs	CN¥372.90k	0.43% CN¥ 47.0m
Xi Ping Zhao	VP & Director	1.9yrs	CN¥372.90k	0.92% CN¥ 101.3m
Wen Tan	Non-Independent Director	4.9yrs	CN¥72.00k	Veri yok
Pengan Shan	Non-Independent Director	7.9yrs	CN¥72.00k	Veri yok
Ruichao Lin	Independent Director	4.9yrs	CN¥72.00k	Veri yok
Qinggong Wu	Independent Director	4.9yrs	CN¥72.00k	Veri yok
So Hyun Lee	Supervisor	7.9yrs	Veri yok	Veri yok
Xiaorong Mou	Independent Director	2.5yrs	CN¥45.00k	Veri yok
Zhenyou Tan	Chairman of the Supervisory Board	1.9yrs	Veri yok	Veri yok
Hougan Huang	Employee Supervisor	less than a year	Veri yok	Veri yok

4.9yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002317 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).

Guangdong Zhongsheng Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Board Elections

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.084 (vs CN¥0.082 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.088 in 2Q 2023)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.20 announced

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.17 in 1Q 2023)

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 26%

Investor sentiment deteriorates as stock falls 17%

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.082 (vs CN¥0.059 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Second quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.16 in 2Q 2022)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 May 2023

Investor sentiment deteriorates as stock falls 20%

Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.35 in FY 2021)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Board Elections

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.032 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.29 in 2Q 2021)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 678.8 million in funding

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Cash Dividend, Payable on May 27, 2022

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2021

Investor sentiment deteriorated over the past week

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.07 in 1Q 2021)

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.032 (vs CN¥0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.17 in 2Q 2020)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2020

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2020

First quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.07 in 1Q 2020)

New 90-day low: CN¥8.13

New 90-day low: CN¥9.73

New 90-day low: CN¥12.06

New 90-day low: CN¥12.11

Third quarter earnings released

New 90-day low: CN¥13.12

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥14.14

Shanghai Yongwei Biotechnology Co., Ltd. completed the acquisition of Guangdong Zhongqiang Pharmaceutical Co., Ltd. from Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317).

Earnings released

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş